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Background: This is a long-term follow-up clinical study of adolescents and adults, survivors of childhood cancer.
We evaluate and analyze the late somatic sequelae of childhood cancer treatment. Many such studies are
susceptible to a strong selection bias, i.e., they employ a limited non-systematic sample of patients, based on a
clinical hospital that provided the cancer treatment or performed the follow-up. To address the issue of selection
bias, we perform here an analysis of late sequelae on a systematic database of the entire population of the children
treated for cancer in Slovenia. Due to the specifics of cancer treatment procedures in Slovenia, they have all been
treated and followed-up in the same clinic.
Methods: The data are based on the centralized registry of cancer patients in Slovenia and present a controlled
and homogeneous collection. Late sequelae are evaluated following a modified CTCAE, i.e., the National Cancer
Institute’s Common Terminology Criteria for Adverse Events version 3.0. We use survival analysis method to
estimate the incidence of and risk for late sequelae, where the time variable is measured in years from the
diagnosis date, while we follow the event of incidence of late sequelae scored other than none. Survival analysis is
performed using KaplanMeier estimator and Cox regression model.
Results: The incidence of mild, moderate, or severe late sequelae of childhood cancer treatment significantly
decreased from 75% in the group of patients diagnosed before 1975 to 55% for those diagnosed after 1995. The
Cox regression analysis of the risk factors for the incidence of late sequelae identifies three significant factors:
treatment modalities, age at diagnosis, and primary diagnosis.
Conclusions: The change of treatment modalities in terms of replacement of surgery and radiotherapy with
chemotherapy is the main reason for the decrease of the incidence and the risk for late sequelae of childhood
cancer treatment; treatment modalities including surgery significantly increase the risk ratio of late sequelae, while
those based on chemotherapy only significantly decreases the risk. Risk of late sequelae increases with the
diagnosis age: younger children are more susceptible to late effects of treatment. Finally, primary diagnosis
significantly influences the risk for late sequelae, but mostly due to the dependency of the treatment modality on
the primary diagnosis.Background
In Slovenia and in the rest of Europe as well as the USA,
the mortality rate of chlidren with cancer is declining
despite the increasing incidence rate. Survival of children
treated for cancer has significantly improved after 1970
with the introduction of chemotherapy. Since 1990, how-
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reproduction in any medium, provided the orreasons: on one hand, new ways of treatment have been
introduced and on the other hand, the mortality due to
late effects of treatment and secondary tumors have
emerged [1-7]. With the increasing number of childhood
cancer survivors, late sequelae and quality of life have be-
come a major concern. Approximately 50% of children
cured of cancer will display one or more delayed somatic
sequelae, and about one third will have severe and life
threatening complications. There is therefore a general
agreement for the necessity of a long-term follow-up of
adolescents and adults, survivors of childhood cancer
[8-12].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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term follow-up clinical studies do not appropriately rep-
resent the entire survivor population for different rea-
sons. One is that not all the patients included in the
follow-up respond to the questionnaires or show-up for
the regular clinical checks. Another reason is selection
bias; studies often address a non-systematic sample of
patients based on a clinical hospital that provided the
treatment or performed the follow-up. Integrating
groups of patients from different follow-up programs or
clinics in a more systematic sample of patients is often
prohibitive, since there are many different approaches to
the evaluation of the late sequelae and quality of life. Fi-
nally, that there are still many open issues related to the
childhood cancer survivors, such as definitions of the
terms cure, health, or quality of life. Even the excellent
studies on large populations of patients and based on
high-quality questionnaires may be susceptible to selec-
tion bias [13-15].
In this paper, we address the problem of selection bias
by performing a study of late sequelae on the entire
population of all registered children treated for cancer in
Slovenia. Namely, the registration of cancer patients in
Slovenia is obligatory and centralized within the Cancer
Registry of Slovenia, established in 1950. Treatment of
children with cancer is also centralized at the Children’s
Hospital in Ljubljana. After treatment, all patients are
being followed at the same single center for at least five
years or until they are 18 years old, and later they are
followed regularly at a single institution, the outpatient
Clinic for Late Effects at the Institute of Oncology,
Ljubljana. The follow-up program that includes a specif-
ically designed questionnaire for recording data has been
established in 1986 [16]. Slovene Ministry of Science has
been financing the program for “Late effects of child-
hood cancer treatment” since 1993. Survivors included
in the program have been evaluated and analyzed as to
their late somatic sequelae including neurological defi-
cits [17], endocrine function deficits [18], renal function
damage [19], secondary tumors [20,21], cardiac damage
[22], and psychosocial consequences [23].
With increased knowledge about late effects of cancer
treatment, treatment policies have been appropriately
changed in order to decrease toxic sequelae [24]. For
example, Hodgkin's disease treatment with MOPP
(i.e., Nitrogen Mustard, Oncovin, procarbazine, and
prednisone), known for causing male sterility, has been
replaced by other chemotherapy (CHT) combinations,
while the doses of radiation have been diminished. In
nephroblastoma, radiotherapy (RT) has been replaced in
the great majority of patients by chemotherapy. The
toxic dose of antracyclines has been avoided in newer
combinations of CHT and RT doses have been dimin-
ished in many cases of soft tissue sarcoma as well. Inmore general terms, while in the first decade until 1970
the great majority of children were treated with surgery
and RT, in the 1970-ies to 1980-ies for the majority of
patients a combination of RT and CHT has been added
to surgery. After 1985, RT was often replaced by CHT.
Because RT has been shown as the major risk for late se-
quelae, it is reasonable to expect a decrease of late se-
quelae in our patients treated after 1985.
The aim of this study is to find out whether the risk
for late somatic sequelae has declined with the treatment
changes described above. Our study includes all children
diagnosed and treated with cancer in Slovenia between
1957 and 2005. The continuous effort on systematic and
unified follow-up of all childhood cancer survivors in
Slovenia allows us to perform a systematic study and
analyze the impact of the treatment advances and
changes to the quality of their life.
Methods
Patients
The study is based on a systematic database of 2005
children aged 16 years or less registered at the Cancer
Registry of Slovenia from 1957 to 2005. Twenty-two
have been excluded from the study: nine were lost from
follow-up immediately after treatment and for thirteen
patients the revision of the primary diagnosis proved
that the tumors were not malignant.
Of the remaining 1983 patients, 1130 have not been
followed for different reasons: 850 died prior to the first
follow-up evaluation, 247 are not eligible for evaluation
yet (they are either younger than 18 years or have been
treated less than five years ago), 14 refused follow-up,
and 19 have been lost from follow-up. Table 1 sum-
marizes the data about the remaining 853 patients in the
study group, including information on gender, age at
diagnosis, diagnosis, secondary tumor incidence, ther-
apy, and current status by the diagnosis period.
The childhood cancer survivors are followed until they
are 18 years old at the Center for treatment of children
with cancer at the Children’s Hospital. After that, physi-
cians that were involved in the primary treatment collab-
orate in the follow-up for late effects performed at the
next-door Oncological Institute. The children and their
parents are well informed about the necessity of a life-
time follow-up by the psychologist that joins the team
during treatment. Every childhood cancer survivor is for-
mally invited to a follow-up evaluation and receives a
booklet with the necessary information [25]. The great
majority of them, 853 in total, accept our recommenda-
tion of a lifetime follow-up, resulting in data from not
only newly treated patients but also those treated dec-
ades ago. The first follow-up evaluation is performed at
least five years after the first treatment and at the age of
18 years.
Table 1 Patient database summary
Diagnosis period
Patients 1957-1975 1976-1980 1981-1985 1986-1990 1991-1995 1996-2005
Female 376 39 46 54 69 63 105
Male 477 56 69 89 103 75 85
Age at diagnosis up to 5 years 248 38 38 59 69 39 5
From 5 to 10 years 216 28 44 41 39 37 27
From 10 to 18 years 389 29 33 43 64 62 158
Leukemia 174 13 23 32 41 35 30
CNS 144 24 18 20 30 23 29
HD 123 11 16 24 24 17 31
NHL 87 6 8 17 22 14 20
Renal tumors 45 9 9 11 10 5 1
Neuroblastoma 25 4 3 5 6 6 1
Rhabdomyosarcoma 34 3 6 5 7 9 4
Malignant bone tumors 51 4 4 9 7 8 19
Soft-tissue sarcomas 65 9 13 11 11 9 12
Other carcinomas 70 8 8 3 5 9 37
Other malignant neoplasms 35 4 7 6 9 3 6
No secondary tumor 736 69 92 117 154 128 176
Secondary tumor 117 26 23 26 18 10 14
Surgery 489 66 71 76 100 73 103
Radio therapy 515 74 76 105 110 61 89
Chemo therapy 590 27 82 113 137 101 130
Alive 808 81 106 136 166 135 184
Dead 45 14 9 7 6 3 6
All 853 95 115 143 172 138 190
Summary of the data collected from the Cancer Registry of Slovenia for the 853 patients in the study group by diagnosis period. The figures report number of
patients by gender, age at diagnosis, diagnosis, the incidence of secondary tumor, therapy and life status.
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For each follow-up evaluation, the examining physician
follows a questionnaire and registers all findings using
his clinical judgment. During the 24 years starting from
1986, two clinical investigators have regularly followed
the patients in close mutual cooperation, working simul-
taneously at the outpatient clinic. For scoring of late
somatic sequelae, we used a modification of The Na-
tional Cancer Institutes Common Terminology Criteria
for Adverse Events version 3.0 (CTCAE), which includes
the classification of organs, the evaluation of the degree
of late effects, and the scoring system. The scoring sys-
tem used in this study, presented in Table 2, is closely
related to the scoring system used earlier in a report
from the childhood cancer study [26]. However, due to
the limited number of patients, some score groups have
been merged together following a clinical examination of
the patient at the outpatient clinic. Patients with no clin-
ical symptoms and pathological laboratory test that does
not require medical treatment have been classified not
to have late sequelae (score 0 in Table 2). Not all
patients, namely, were subjected to a laboratory test andtherefore, the results could not represent the whole
series. Patients where deviations from normal findings
could not be expected were exluded from laboratory
testing, e.g., a patient with only surgical treated glioma
of the optic nerve was not subjected to evaluation of
endocrine organs, pulmonary function, or kidney func-
tion. He was blind on one eye and his sequaelae is classi-
fied as moderate (score 2 in Table 2). For a more
detailed description of the scoring system, check the
Additional file 1.
We applied the scoring system on three follow-up eva-
luations of each patient: at the first evaluation of the late
effects, at the follow-up performed in December 2007,
and at the last follow-up prior to this study performed
in December 2010. The graph in Figure 1(b) shows that
the incidence of somatic late sequelae increases with the
time period after treatment. At the fist evaluation, al-
most 40% of patients have no sequelae, while at the third
evaluation in 2010, the percentage of patients with no
sequelae drops to slightly more than 20%. The box plot
graphs in Figure 1(a) show that the time period from the
treatment to the first follow-up evaluation varies a great
Table 2 Late-sequelae scoring system
Score Description
0 (none) No effect that can be related to cancer
treatment or an effect so mild that it
requires no regular medication or other
healthcare intervention and does not
interfere with normal life.
1 (mild) Mild effects related to cancer treatment
that are entirely or almost entirely
controlled by medicine and/or other
healthcare intervention and do not lead
to anything more than a minor
alternation in lifestyle.
2 (moderate) Moderate adverse effects related to cancer
treatment that require continued use of
medicine and/or other healthcare intervention.
The patient remains able to lead an
independent existence although some
modifications in activity and in style of
leaving are necessary.
3 (severe) Severe adverse effects. The patient’s life is
considerably affected by the adverse
effects related to cancer treatment with a
considerable and continued restriction of
activities. Inpatient care and major surgery
might have been required.
4 (death) Death related to the cancer and/or
cancer treatment.
The system for scoring late somatic sequelae of childhood cancer and
treatment used in our study adapted from [26].
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treatment (the bottom whisker of the left-most boxplot),
which happens in the cases where secondary tumor is
diagnosed soon after the treatment of the primary one,
or more than 40 years after treatment (the top whisker
of the left-most boxplot). For example, a two-year old
child treated for Wilm's tumor in 1990, had his first
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Figure 1 Late sequelae evaluations. The period between the diagnosis a
patients with different evaluation scores from Table 2 (right-hand side, b), f
performed in December[3], and the third one in December 2010.(in 2006), while a 15-year old patient with NHL, treated
the same year, had his first evaluation 5 years after treat-
ment (in 1995).
To study sequelae at a fixed time period (of five and
ten years) after treatment, we “extrapolated” the sequelae
score. For the patients with no sequelae, 10 or more
years after treatment, we assume that no sequelae have
been observed before the first evaluation date and also
five or ten years after treatment. On the other hand,
those who had severe sequelae in early years after treat-
ment (at the date of diagnosis of the first secondary can-
cer) were assumed to have severe sequelae also in the
future. Those with moderate score, if there was no
change between the first and second evaluation, could
be considered to have the same score five years after
treatment. Using this method, we were able to “extrapo-
late” the sequelae five and ten years after treatment for
832 and 785 patients, respectively. Table 3 summarizes
the data about the change of the “extrapolated” late
somatic sequelae scores for patients in the study group
five and ten years after treatment through different diag-
nosis periods.
Data analysis methods
Table 3 depicts a trend of increasing percentage of
patients with no sequelae five or ten years after treat-
ment through diagnosis periods, from 24% of patients
diagnosed and treated before 1975 to almost 50% of
those diagnosed between 1991 and 1996. This decrease
in the incidence of late sequelae coincides with the dy-
namic of treatment modalities depicted in Figure 2. Be-
fore 1975, most of the patients were treated with a
combination of surgery and radiotherapy, while after
1975 chemotherapy treatment prevails. Our hypothesis
is that the dynamic change of the therapy combinationsfollow up evaluation













                                                    (b)
nd the follow-up evaluation (left-hand side, a) and the percentage of
or the first follow-up evaluation after treatment, the second one
Table 3 Late-sequelae scores
Years after treatment Sequelae score Patients, % Diagnosis period
1957-1975 1976-1980 1981-1985 1986-1990 1991-1995 1996-2005
Five 0 (none) 318, 37.3% 23, 24.2% 29, 25.2% 42, 29.4% 72, 41.9% 68, 49.3% 84, 44.2%
1 (mild) 299, 35.1% 40, 42.1% 45, 39.1% 55, 38.5% 73, 42.4% 40, 29.0% 46, 24.2%
2 (moderate) 157, 18.4% 18, 18.9% 28, 24.3% 31, 21.7% 18, 10.5% 19, 13.8% 43, 22.6%
3 (severe) 50,5.9% 6,6.3% 7,6.1% 9,6.3% 8,4.7% 9,6.5% 11, 5.8%
4 (death) 8,0.9% 0,0.0% 0,0.0% 1,0.7% 1,0.6% 1,0.7% 5,2.6%
Unknown 21,2.5% 8,8.4% 6,5.2% 5,3.5% 0,0.0% 1,0.7% 1,0.5%
Ten 0 (none) 271, 31.8% 21, 22.1% 26, 22.6% 37, 25.9% 67, 39.0% 66, 47.8% 54, 28.4%
1 (mild) 241, 28.3% 25, 26.3% 33, 28.7% 48, 33.6% 63, 36.6% 38, 27.5% 34, 17.9%
2 (moderate) 186, 21.8% 33, 34.7% 33, 28.7% 37, 25.9% 28, 16.3% 21, 15.2% 34, 17.9%
3 (severe) 71,8.3% 8,8.4% 15, 13.0% 16, 11.2% 10, 5.8% 10, 7.2% 12, 6.3%
4 (death) 16,1.9% 1,1.1% 2,1.7% 1,0.7% 4,2.3% 2,1.4% 6,3.2%
Unknown 68,8.0% 7,7.4% 6,5.2% 4,2.8% 0,0.0% 1,0.7% 50, 26.3%
Late somatic sequelae scores for the 853 patients in the study group five and ten years after treatment by diagnosis period. The figures report number and
percentage of patients with different late-sequelae scores.
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sequelae.
To test this central hypothesis, we use survival analysis
methodology that allows analysis of the survival time of
patients. In general, survival analysis can tackle the oc-
currence of any particular event of interest and not only
death. In our study, the event of interest is late sequelae;
more specifically, we follow the occurrence of late se-
quelae. We measure the time to the occurrence of late
sequelae in years from date of the diagnosis and treat-
ment of the primary tumor. We censor data about the
patients that do not reach late sequelae evaluation other





















Figure 2 Treatments through diagnosis periods. Percentages of patient
diagnosis periods.To measure the probability of late sequelae occurrence
five and ten years after treatment, we use Kaplan-Meier
estimator [27]. We also analyze the hazard function that
models the late-sequelae risk, i.e., the probability that
the patient has late sequelae other than none at a certain
time after treatment. Using a Cox’s proportional hazards
model, commonly referred to as Cox regression [28], we
analyze the impact of demographic, diagnosis, and treat-
ment factors on the late-sequelae risk (hazard ratio). All
tests of significant differences are two-sided with a sig-
nificance level of 95%. The statistical analysis is per-






s that received surgery, radiotherapy, and chemotherapy in different
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Late-sequelae occurrence and risk through diagnosis
periods
Figure 3 depicts the dynamic change of the probability
that a patient does not have late sequelae five and ten
years after treatment through different diagnosis periods.
The figure shows the expected small and consistent de-
crease of the probability when the observation period
extends from five to ten years. More importantly, the
figure also shows increase of the probability for no se-
quelae through time. For the patients treated in the ini-
tial periods from 1957 to 1985, the probability is almost
constant and below 30%. After 1986, we observe a steep
increase of the no-sequelae probability up to the max-
imal value of almost 50% in the period from 1991 to
1995.
Since the observed change of probability seems to be
correlated to the change of therapy modalities depicted
in Figure 2, we continue our analysis with the analysis of
the treatment modalities on the occurrence of late se-
quelae. Note that one patient with neuroblastoma diag-
nosed at birth has not received any treatment; we
excluded that patient data from the further analysis.
Influence of therapy on the late-sequelae risk
Figure 4 represents the Kaplan-Meier estimate of prob-
ability that a patient has no late effects five and ten after
treatment. The figure shows that surgery and RT are
much more offensive in terms of late sequelae than
CHT. The probability of no late effects is slightly above
50% for patients that have not been subjected to surgery






















Figure 3 Late sequelae five and ten years after treatment. The Kaplan-
thereof) that a patient will not have any signs of late sequelae (i.e., the seq
circles) after treatment. The graph depicts the dynamic change of the probthat have been treated with surgery. Similarly, the same
probability significantly drops from about 45% for
patients that have not been treated with RT to slightly
below 30% for patients subjected to RT. On the other
hand, the probability of no late effects is about 35% for
both patients with or without CHT.
These results confirm our hypothesis that the
improvements of therapy combinations have a strong
impact on the decrease of late-sequelae incidence. How-
ever, to test the importance of therapy combination rela-
tive to other factors, we perform a multivariate Cox
regression analysis.
Relative importance of late-sequelae risk factors
Table 4 reports the results of the multivariate analysis in
terms of the relative impact of gender, age at diagnosis,
diagnosis period, therapy, and primary diagnosis on the
late sequelae hazard ratio. As expected, gender does not
influence the risk for late sequelae: there is only insig-
nificant (p = 0.06) difference between the risk in the
reference group of females (hazard ratio of 1.0) and
males (hazard ratio of 0.85). On the other hand, age at
diagnosis has a significant impact on the late-sequelae
risk: it decreases with increasing age. For the group of
patients diagnosed at the age between 5 and 10 years as
well as 10 and 16 years, late-sequelae risk is significantly
lower as compared to the reference group of patients
diagnosed when less than 5 years old (hazard ratios of
0.65 and 0.40 as compared to the reference value of 1,
with both p-values lower than 0.01).
Results on the impact of treatment reconfirm our find-
ings about the significant impact of the treatmentosis period
1986−1990 1991−1995 1996−
Meier estimates of the probabilities (and the confidence intervals
uelae score will be 0 or none) five (white circles) and ten years (black































Figure 4 Influence of treatment on late sequelae incidence. The influence of individual therapeutic treatment on the Kaplan-Meier estimates
of the probabilities (and the confidence intervals thereof) that a patient does not have late sequelae, i.e., the sequelae score of 0 or none is
observed, five years (white circles) and ten years (black circles) after treatment.
Erman et al. BMC Research Notes 2012, 5:254 Page 7 of 10
http://www.biomedcentral.com/1756-0500/5/254modality on the late-sequelae risk. Following the results,
we can identify three categories of treatment modalities.
The first category of patients treated with S only and
CHT only has low late-sequelae risk (the hazard ratio of
1 and 0.96). Furthermore, the second category has
medium risk and includes patients treated with RT only
(hazard ratio of 1.91), a combination of RT and CHT
(hazard ratio of 2.29), or a combination of surgery and
CHT (hazard ratio of 2.49). Finally, patients in the third
category with high risk for late sequelae include those
treated with the combinations of surgery and RT (hazard
ratio of 3.25) or surgery, RT, and CHT (hazard ratio of
3.80).
Another significant risk factor turns out to be primary
diagnosis. The reference group of patients diagnosed
with leukemia has a significantly lower late-sequelae risk
compared to any other primary diagnosis. However, a
deeper analysis of the dependence of treatment on diag-
nosis, presented in Table 5, shows that this is mostly due
to the treatment modalities applied in the context of the
primary diagnosis. Majority of Leukemia patients (97%)
were treated with CHT only (a treatment modality with
the lowest late-sequelae risk) or a combination of RT
and CHT (a treatment modality with medium late-se-
quelae risk). Similarly, in the group of patients diagnosed
with NHL (hazard ratio of 1.82), 67% of the patients
were treated following these two modalities. On the
other hand, none of the patients diagnosed with renal
tumors (the group with the highest hazard ratio of 6.02)
received CHT only or a combination of RT and CHT
and 47% received the most invasive combination of sur-
gery, RT, and CHT. From the results presented in Table
5, we can conclude that the impact of the primarydiagnosis on the late-sequelae can be mostly explained
through its influence on the selection of the treatment
modality.
Discussion
The survival analysis of childhood cancer patients has
been used in a number of other studies, including a
study of the same data in Slovenia [1]. In the context of
late sequelae, survival analysis has been recently used in
[2], where CTCAE has been applied to evaluate late
somatic sequelae of 519 childhood cancer survivors with
late sequelae other than none. The results on the inci-
dence of late sequelae are similar to the results of our
study; most of the late sequelae other than none are
mild or moderate. The study also identifies four risk fac-
tors for severe sequelae of childhood cancer treatment:
minority race, diagnosis of other tumor, older age at
diagnosis, and a history of stem cell transplant. The
comparison with our analysis of risk factors for any late
sequelae other than none, reveals a single common fac-
tor of age. However, in our study, results show that
higher age at diagnosis lowers the risk for late sequelae.
Other studies of childhood cancer survival and seque-
lae confirm our results on significant improvements
gained through different diagnosis periods especially
after 1980, while no decrease in the late mortality rate
by treatment period (the periods being 1960–1970 and
1971–1984) has been identified in [30].
Conclusions
Although there is general agreement on the need for life-
long follow-up of childhood cancer survivors, the transfer
of former patients from pediatric to satisfactory adult
Table 4 Late-sequelae hazard ratios for different risk
factors
Risk factor HR CI P
Gender: Female (reference group) 1.00
Male 0.85 0.71–1.00 0.06
Age: from 0 to 5 years (reference group) 1.00
From 5 to 10 years 0.65 0.51–0.84 <0.01
From 10 to 16 years 0.40 0.31–0.52 <0.01
Diagnosis period: 1957-1975 (reference group) 1.00
1976-1980 1.15 0.83–1.59 0.41
1981-1985 1.22 0.89–1.68 0.21
1986-1990 1.02 0.74–1.41 0.89
1991-1995 0.90 0.63–1.28 0.56
1996-2005 1.14 0.81–1.61 0.45
Treatment: Surgery only (S, reference group) 1.00
Radiotherapy only (RT) 1.91 1.06–3.47 0.03
Chemotherapy only (CHT) 0.96 0.53–1.74 0.88
Surgery and Radiotherapy (S_RT) 3.25 2.31–4.57 <0.01
Surgery and Chemotherapy (S_CHT) 2.49 1.76–3.54 <0.01
Radio and Chemotherapy (RT_CHT) 2.29 1.54–3.40 <0.01
Surgery, Radio and Chemotherapy (S_RT_CHT) 3.80 2.71–5.32 <0.01
Primary diagnosis: Leukemia (reference group) 1.00
NHL 1.82 1.21–2.74 <0.01
Neuroblastoma 2.27 1.23–4.20 0.01
Other malignant neoplasms 2.93 1.69–5.06 <0.01
Rhabdomyosarcoma 2.97 1.79–4.93 <0.01
HD 3.09 2.14–4.45 <0.01
CNS 3.60 2.33–5.55 <0.01
Soft-tissue sarcomas 4.00 2.51–6.38 <0.01
Malignant bone tumors 4.54 2.81–7.31 <0.01
Other carcinomas 4.62 2.73–7.84 <0.01
Renal tumors 6.02 3.71–9.76 <0.01
Cox regression estimates of the late sequelae hazard ratios (HR) by gender,
age at diagnosis, diagnosis period, therapy, and primary diagnosis, 95%
confidence intervals (CI) thereof, and the p-values for the test of the significant
difference from the indicated reference groups.
Table 5 Treatment modality by primary diagnosis
Treatment
Primary diagnosis S RT CHT S_RT S_CHT RT_CHT S_RT_CHT
Leukemia 0.6% 1.1% 27.0% 0.6% 0.0% 70.1% 0.6%
NHL 2.3% 3.4% 25.3% 3.4% 16.1% 41.4% 8.0%
Neuroblastoma 37.5% 4.2% 0.0% 8.3% 25.0% 4.2% 20.8%
Other malignant
neoplasms
40.0% 2.9% 2.9% 20.0% 25.7% 0.0% 8.6%
Rhabdomyosarcoma 2.9% 0.0% 0.0% 0.0% 20.6% 29.4% 47.1%
HD 0.0% 5.7% 4.1% 8.9% 1.6% 59.3% 20.3%
CNS 31.9% 3.5% 0.0% 35.4% 2.1% 2.8% 24.3%
Soft-tissue sarcomas 24.6% 0.0% 0.0% 10.8% 50.8% 1.5% 12.3%
Malignant bone
tumors
3.9% 0.0% 0.0% 7.8% 60.8% 13.7% 13.7%
Other carcinomas 60.0% 2.9% 0.0% 18.6% 5.7% 4.3% 8.6%
Renal tumors 2.2% 0.0% 0.0% 11.1% 40.0% 0.0% 46.7%
The influence of the primary diagnosis on the treatment modality.
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jority of childhood cancer survivors do not receive recom-
mended risk-based care [34]. The small country of
Slovenia is, in this respect, in an advantageous position,
with one pediatric center for treatment in close cooper-
ation with the adult outpatient clinic at the Oncological
Institute. The main advantage of the study presented here
is that it is performed on a systematic database of the en-
tire population of the children cancer patients in Slovenia
[10] that have been continuously followed-up in the same
clinic under the unique opportunity for an » ongoing com-
munication between the cancer center that provided acute
care for the patient and the healthcare facility providing
follow-up care « [35].The results of the Kaplan-Mayer analysis show that
the incidence of late sequelae in childhood cancer
patients five and ten years after treatment in Slovenia
steadily decreases from 75% in the group of patients
diagnosed before 1975 to 55% in the patients diagnosed
after 1995 (see Table 3). The results show that the im-
pact of individual therapies on late sequelae incidence
differs: we observe a high and significant impact of sur-
gery on the incidence of late sequelae five and ten years
after treatment, a lower but still significant impact of
radiotherapy, and almost no impact of chemotherapy
(see Figure 4).
The Cox regression analysis of late-sequelae risk
reveals that three studied factors significantly influence
the risk. The most important factor is the treatment mo-
dality. Combinations of treatments that include surgery
significantly increase the risk for late sequelae: the esti-
mated hazard ratio of 3.80 for the combination of sur-
gery, radio-, and chemotherapy, 3.25 for the
combination of surgery and radiotherapy, and 2.49 for
surgery and chemotherapy (see Table 4). Furthermore,
age at diagnosis also significantly influences the hazard
ratio for late sequelae from 1 for the reference group of
patients diagnosed when below 5 years of age to signifi-
cantly lower ratios of 0.65 and 0.40 for the patients diag-
nosed between 5 and 10 years as well as 10 and 16 years
of age, respectively (see Table 4). Finally, the primary
diagnosis also significantly influences the risk for late se-
quelae, with Leukemia leading to significantly lower late-
sequelae risk as compared to all other diagnoses and
renal tumors leading to the highest hazard ratio (see
Table 4). However, deeper analysis of these results (see
Table 5) shows that this is mostly due to the selection of
the appropriate treatment modality for the specific pri-
mary cancer diagnosis.
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http://www.biomedcentral.com/1756-0500/5/254In this paper, we focus on the influence of individual
risk factors on incidence of and risk for late sequelae
other than none. Two directions for immediate further
work are evident. First, survival analysis can be used to
explore the incidence of and risk for more serious (mild,
moderate, or severe) somatic sequelae. Second, survival
analysis can be combined with multivariate statistical
methods to further explore the interactions among dif-
ferent risk factors with respect to their joint influence on
the late sequelae of childhood cancer treatment.
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